» Articles » PMID: 11115819

Oral Glutamine in the Prevention of Fluorouracil Induced Intestinal Toxicity: a Double Blind, Placebo Controlled, Randomised Trial

Overview
Journal Gut
Specialty Gastroenterology
Date 2000 Dec 15
PMID 11115819
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Background: 5-Fluorouracil (FU) in association with folinic acid (FA) is the most frequently used chemotherapeutic agent in colorectal cancer but it often causes diarrhoea. Animal and human studies suggest that glutamine stimulates intestinal mucosal growth.

Aim: To determine if oral glutamine prevents changes in intestinal absorption (IA) and permeability (IP) induced by FU/FA.

Methods: Seventy chemotherapy naive patients with colorectal cancer were randomly assigned to oral glutamine (18 g/day) or placebo before the first cycle of FU (450 mg/m(2)) and FA (100 mg/m(2)) administered intravenously for five days. Treatment was continued for 15 days, starting five days before the beginning of chemotherapy. IA (D-xylose urinary excretion) and IP (cellobiose-mannitol test) were assessed at baseline and four and five days after the end of the first cycle of chemotherapy, respectively. Patients kept a daily record of diarrhoea, scored using the classification system of the National Cancer Institute (Bethesda, Maryland, USA). Duration of diarrhoea was recorded and the area under the curve (AUC) was calculated for each patient.

Results: Baseline patient characteristics and basal values of IP and IA tests were similar in the two arms. After one cycle of chemotherapy, the reduction in IA (D-xylose absorption) was more marked in the placebo arm (7.1% v 3. 8%; p=0.02); reduction of IP to mannitol was higher in the placebo arm (9.2% v 4.5%; p=0.02); and urinary recovery of cellobiose was not different between the study arms (p=0.60). Accordingly, the cellobiose-mannitol ratio increased more in the placebo arm (0.037 v 0.012; p=0.04). Average AUC of diarrhoea (1.9 v 4.5; p=0.09) and average number of loperamide tablets taken (0.4 v 2.6; p=0.002) were reduced in the glutamine arm.

Conclusions: Glutamine reduces changes in IA and IP induced by FU and may have a protective effect on FU induced diarrhoea.

Citing Articles

Glutamine Supplementation as an Anticancer Strategy: A Potential Therapeutic Alternative to the Convention.

Muranaka H, Akinsola R, Billet S, Pandol S, Hendifar A, Bhowmick N Cancers (Basel). 2024; 16(5).

PMID: 38473414 PMC: 10930819. DOI: 10.3390/cancers16051057.


L-Glutamine and Survival of Patients with Locally Advanced Head and Neck Cancer Receiving Chemoradiotherapy.

Tsujimoto T, Wasa M, Inohara H, Ito T Nutrients. 2023; 15(19).

PMID: 37836400 PMC: 10574413. DOI: 10.3390/nu15194117.


Combination L-Glutamine with Gemcitabine and Nab-Paclitaxel in Treatment-Naïve Advanced Pancreatic Cancer: The Phase I GlutaPanc Study Protocol.

Gong J, Osipov A, Lorber J, Tighiouart M, Kwan A, Muranaka H Biomedicines. 2023; 11(5).

PMID: 37239063 PMC: 10216251. DOI: 10.3390/biomedicines11051392.


Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity.

Tao G, Huang J, Moorthy B, Wang C, Hu M, Gao S Expert Opin Drug Metab Toxicol. 2020; 16(11):1109-1124.

PMID: 32841068 PMC: 8059872. DOI: 10.1080/17425255.2020.1815705.


Current topical trends and novel therapeutic approaches and delivery systems for oral mucositis management.

Al-Taie A, Al-Shohani A, Albasry Z, Altaee A J Pharm Bioallied Sci. 2020; 12(2):94-101.

PMID: 32742107 PMC: 7373116. DOI: 10.4103/jpbs.JPBS_198_19.


References
1.
Baskerville A, Hambleton P, Benbough J . Pathological features of glutaminase toxicity. Br J Exp Pathol. 1980; 61(2):132-8. PMC: 2041515. View

2.
Bjarnason I, Macpherson A, Hollander D . Intestinal permeability: an overview. Gastroenterology. 1995; 108(5):1566-81. DOI: 10.1016/0016-5085(95)90708-4. View

3.
TREMEL H, Kienle B, Weilemann L, Stehle P, Furst P . Glutamine dipeptide-supplemented parenteral nutrition maintains intestinal function in the critically ill. Gastroenterology. 1994; 107(6):1595-601. DOI: 10.1016/0016-5085(94)90797-8. View

4.
Baskerville A . Intestinal lesions induced experimentally by methotrexate. Br J Exp Pathol. 1977; 58(6):663-9. PMC: 2041291. View

5.
Poon M, Oconnell M, MOERTEL C, Wieand H, Cullinan S, Everson L . Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol. 1989; 7(10):1407-18. DOI: 10.1200/JCO.1989.7.10.1407. View